In 2023, Finland led European Nervous System Medicine sales per capita at $106.7 PPP, reflecting robust annual growth of 11.29%. In contrast, Greece and Ireland saw declines of 3.3% and 1.66%, respectively. Luxembourg demonstrated modest growth of 1.6%, while Italy and Latvia posted significant increases at 5.47% and 6.35%, respectively. Over the past five years, Finland and Latvia show steady upward trends, likely driven by innovation and increased healthcare investments.
Future trends to monitor include:
- The impact of demographic shifts and aging populations on medicine demand.
- Regulatory changes affecting market dynamics and pricing structures.
- Technological developments in pharmaceutical treatments and their adoption rates.
Top countries in Nervous System Medicine Sales by Country
| # | 6 Countries | US Dollars PPP Per Capita | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Finland | 106.7 | 2023 | +11.61% | +11.29% | View data |
| 2 | 2 Greece | 93.6 | 2023 | -5.36% | -3.3% | View data |
| 3 | 3 Luxembourg | 74.5 | 2023 | +0.54% | +1.6% | View data |
| 4 | 4 Ireland | 68.7 | 2023 | -0.87% | -1.66% | View data |
| 5 | 5 Italy | 56.9 | 2023 | +4.21% | +5.47% | View data |
| 6 | 6 Latvia | 56.2 | 2023 | +1.63% | +6.35% | View data |
